The patent will protect the Elite’s proprietary formulation for abuse resistant products utilizing the pharmacological approach. Elite, which develops oral sustained and controlled release products, has additional patents
Wellstat grants rights for use of uridine triacetate as an antidote to overexposure to the chemotherapy drug 5-fluorouracil (5-FU) due to dosing errors or impaired clearance of 5-FU
The initial agreement was signed in April 2007 and present agreement provides an extension to 2015. Merck will continue to use Codexis’ enzyme products to develop cost- and
As a part of the agreement, the physiological characteristics of the adult autologous vascular cells which form the basis of the IntelliCell product will be discovered. IntelliCell CEO
The collaboration will focus on the radiation oncology research to advance treatment technology. With the signing of collaboration agreement with the University of Heidelberg in March 2012, the
The enzalutamide has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy. The oral once-daily investigational agent is an androgen receptor signalling inhibitor. Enzalutamide
The Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer (MISSION) trial observed an improvement in the secondary endpoint of progression-free survival (PFS). The Nexavar plus
Selexis CEO Igor Fisch said, "Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic." ADIENNE Pharma
BD Live! enables comparative asset analysis via an industry-first Relative Valuation Index (RVI) which accounts for the stage of asset development and factors in competitive environment, scientific evidence,
Dulaglutide, a long-acting glucagon-like peptide 1 (GLP-1) analog, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure (SBP, or pressure while the heart contracts) after
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.